NCT05012423View on ClinicalTrials.gov

FTIH Study of ECC0509 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

July 22, 2023

Study Completion Date

July 22, 2023

Conditions
Nonalcoholic SteatohepatitisOsteoarthritis
Interventions
DRUG

Placebo

Matching Placebo will be administered as oral capsules.

DRUG

ECC0509

ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.

DRUG

Placebo

Matching Placebo will be given orally during each dosing day.

DRUG

ECC0509

ECC0509 1 mg and 10 mg capsules

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

Sponsors

Lead Sponsor

Eccogene
All Listed Sponsors
lead

Eccogene

INDUSTRY

NCT05012423 - FTIH Study of ECC0509 in Healthy Volunteers | Biotech Hunter | Biotech Hunter